Trial | N randomized/evaluable | Treatments (dose) and schedule | Duration |
---|---|---|---|
Carducci, 2004 [85] | 809/809 | atrasentan po (10 mg) | NR |
 |  | placebo |  |
Carducci, 2003 [79] | 288/288 | atrasentan (2.5 mg) po daily | to progression |
 |  | atrasentan (10 mg) po daily |  |
 |  | placebo |  |
Small, 2003 [86] | 127/127 | APC8015 iv q 2 wks × 3 | to progression |
 |  | placebo |  |
Small, 2002 [81] | 390/390 | suramin (3.192 mg/m2)* iv | 3 cycles (12 weeks) |
 |  | suramin (5.320 mg/m2)* iv |  |
 |  | suramin (7.661 mg/m2)* iv |  |
Ahmann, 2001 [87] | 553/406†| prinomastat (5 mg) po twice daily mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily | NR |
 |  | prinomastat (10 mg) po twice daily mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily |  |
 |  | mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily placebo |  |
Small, 2000 [82] | 460/458 | suramin d1: 1000 mg/m2 2-hr iv d2-5: 400 mg/m2, 300 mg/m2, 250 mg/m2, and 200 mg/m2 iv, respectively d8,11,15,19: 275 mg/m2 iv for 2 wks d22,29,36,43,50,57,64,71,78: 275 mg/m2 iv wks 4–12 hydrocortisone (40 mg) po daily | to progression or unacceptable toxicity |
 |  | hydrocortisone po daily placebo |  |
Debruyne, 1998 [83] | 321/321 | liarozole (300 mg) twice daily | to progression or unacceptable toxicity |
 |  | CPA (100 mg) twice daily |  |